| 颜艳 王爽 苏爱军 李琳 张毅 李全民.坎地沙坦联合贝那普利治疗糖尿病肾病并高血压患者的临床研究[J].,2015,15(20):3898-3901 |
| 坎地沙坦联合贝那普利治疗糖尿病肾病并高血压患者的临床研究 |
| Clinical Research on Candesartan Combined with Benazepril for Patientswith Diabetic Nephropathy and Hypertension |
| |
| DOI： |
| 中文关键词: 坎地沙坦 贝那普利 糖尿病肾病 高血压 |
| 英文关键词: Candesartan Benazepril Diabetic nephropathy Hypertension |
| 基金项目: |
|
| 摘要点击次数: 750 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探索坎地沙坦联合贝那普利治疗糖尿病肾病（DN）并高血压患者的临床疗效。方法：选择2012 年7 月至2014 年9 月
我院接收的DN合并高血压患者135 例，按照随机数表法将患者分成坎地沙坦组（口服8 mg/d 坎地沙坦）、贝那普利组（口服10
mg/d 贝那普利）和联合用药组（口服8 mg/d坎地沙坦和10 mg/d 贝那普利）三组，每组45 例，连续治疗12 周。比较三组患者治疗
前后收缩压(SBP) 、舒张压(DBP)、24 h尿微量清蛋白排泄频率(24 h UAER)、尿素氮（BUN）、血钾水平（K+）、血清肌酐（Scr）、肌酐
清除率（Ccr）、空腹血糖（FPG）指标变化及不良反应发生率。结果：与治疗前相比，治疗后各组患者的SBP、DBP、24 h UAER 及
BUN、Scr、Ccr、FPG 均显著下降（均P<0.05），且联合用药组患者的上述各指标水平明显低于坎地沙坦组和贝那普利组（均P<0.
05）；联合用药组不良反应发生率低于其他两组，但是三组之间差异无统计学意义（P>0.05）。结论：坎地沙坦联合贝那普利可以有
效改善DN 并高血压患者的血压情况及尿蛋白水平，改善患者的肾脏功能，且疗效优于单药治疗，对于临床用药有指导意义。 |
| 英文摘要: |
| Objective:To explore the clinical effect of candesartan combined with benazepril in the treatment of patients with
diabetic nephropathy (DN) and hypertension.Methods:A total of 135 patients with DN and hypertension, who were treated in Second
Artillery General Hospital of Beijing from July 2012 to September 2014, were randomly divided into candesartan group (oral
administration of 8mg/d of candesartan, n=45), benazepril group (oral administration of 10mg/d of benazepril, n=45) and combination
group (oral administration of 8 mg/d of candesartan and 10mg/d of benazepril, n=45). All the patients of the three groups were given
continuous treatment for 12 weeks. Then the changes of systolic blood pressure (SBP), diastolic blood pressure (DBP), 24 h urine trace
albumin excretion rate (24 h UAER), urea nitrogen (BUN), potassium (K+), serum creatinine (Scr), creatinine clearance (Ccr), fasting
plasma glucose (FPG) before and after treatment and the incidence of adverse reactions in the three groups were compared.Results:Compared with before treatment, the levels of SBP, DBP, 24 h UAER and BUN, Scr, Ccr, and FPG in the three groups after treatment
significantly decreased (P<0.05), and the levels of above indexes after treatment and the incidence of adverse reaction in combination
group were significantly lower than those in the other two groups(P<0.05). But there was no statistically significant difference among the
three groups (P>0.05).Conclusion:Candesartan combined with benazepril can effectively improve the blood pressure and the level of
urine protein, and the kidney function of the patients with DN and hypertension, its effect is better than the single drug therapy, which can
be used as a guidance for clinical medication. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
